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Abstract
We previously identified cystatin C (CystC) as a novel antagonist of transforming growth factor β (TGF-β) signaling
in normal and malignant cells. However, whether the anti–TGF-β activities of CystC can be translated to preclinical
animal models of breast cancer growth and metastasis remains unproven. Assessing the preclinical efficacy of
CystC was accomplished using metastatic 4T1 breast cancer cells, whose oncogenic responses to TGF-β were
inhibited both in vitro and in vivo. Indeed, we observed CystC to prevent TGF-β from stimulating the growth and
pulmonary metastasis of 4T1 tumors in mice in part by reducing the extent of Smad2, p38 mitogen-activated pro-
tein kinase, and extracellular signal–regulated kinase 1/2 phosphorylation present in 4T1 tumors. We also found
CystC to significantly antagonize angiogenesis in developing 4T1 tumors, suggesting a novel role for CystC in un-
coupling TGF-β signaling in endothelial cells (ECs). Accordingly, CystC dramatically reduced murine and human EC
responsiveness to TGF-β, including their ability to regulate the expression of 1) TGF-β signaling components, 2)
inhibitor of differentiation (ID) family members, and 3) matrix metalloproteinases and their inhibitors (TIMPs) and to
undergo cell invasion and angiogenic sprouting stimulated by TGF-β. Importantly, CystC prevented TGF-β from
stimulating vessel development in Matrigel plugs implanted into genetically normal mice. Collectively, our findings
provide the first preclinical evidence that CystC is efficacious in preventing breast cancer progression and angio-
genesis stimulated by the oncogenic TGF-β signaling system and suggest that CystC-based chemotherapeutics
possesses translational efficacy to one day treat and improve the clinical course of late-stage breast cancers.
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Introduction
Transforming growth factor β (TGF-β) is a multifunctional cytokine
that governs a variety of diverse cellular processes in virtually all cell
types and tissues, including their ability to differentiate, migrate, and
proliferate and to undergo programmed cell death [1,2]. These activ-
ities of TGF-β are particularly pronounced in the mammary gland,
wherein TGF-β regulates all stages of gland development and differ-
entiation and potently suppresses mammary tumorigenesis [3,4].
Quite paradoxically, mammary tumorigenesis converts the functions
of TGF-β in mammary epithelial cells (MECs) from that of a tumor
suppressor to that of a tumor promoter. Once converted, TGF-β
stimulation of late-stage malignant MECs promotes their invasion
and metastasis, which remain the most lethal facets of developing
and progressing mammary tumors [1,3,4]. At present, the precise
nature of the cellular, genetic, and epigenetic events that enable
mammary tumorigenesis to elicit oncogenic signaling and metastasis
stimulated by TGF-β remains incompletely understood. However, it
is known that the efficient dissemination of metastatic breast cancer
cells requires tumor angiogenesis, which facilitates mammary tumor
growth and survival, and provides a route for their eventual meta-
static spread [5,6]. Like invasion and metastasis, angiogenesis is also
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a hallmark of tumorigenesis whose activation and resolution are gov-
erned by TGF-β [7,8]. The duality of TGF-β in regulating angiogen-
esis has been attributed to its activation in endothelial cells (ECs) of
two distinct type I receptors, namely, 1) activin receptor–like kinase 1
(ALK-1), which mediates angiogenesis by stimulating Smad1/5/8,
and 2) TGF-β type I receptor (TβR-I; ALK-5), which mediates an-
giostasis by stimulating Smad2/3 [7–9]. Unfortunately, how ECs ul-
timately distinguish between the proangiogenic and antiangiogenic
signals induced by TGF-β remains to be fully elucidated. Despite
these knowledge gaps, it does stand to reason that developing chemo-
therapeutic interventions capable of preventing TGF-β from stimu-
lating mammary tumor metastasis and angiogenesis will offer new
inroads into improving the clinical course of breast cancer patients.
Cystatin C (CystC) is a ubiquitously expressed secretory protein
that inactivates members of the cathepsin family of cysteine proteases
[10,11]. We identified CystC as a novel TGF-β type II receptor
(TβR-II) antagonist that prevents its ability to bind TGF-β and, con-
sequently, inhibits TGF-β signaling in normal and malignant cells
[12,13]. Indeed, CystC administration inhibits TGF-β stimulation
of gene expression, of epithelial-mesenchymal transition, and of cell
proliferation and morphologic transformation [12,13], suggesting
that CystC possesses therapeutic potential in alleviating oncogenic
signaling stimulated by TGF-β. Despite these interesting in vitro
findings [12,13], a potential role for CystC in suppressing oncogenic
TGF-β signaling in malignant metastatic mammary tumors in vivo
remains unexplored, as does the potential for CystC to inhibit
TGF-β signaling in ECs and their ability to undergo angiogenesis.
As such, the aims of this study were to determine whether CystC
was efficacious in inhibiting the ability of TGF-β to 1) stimulate
the growth and pulmonary metastasis of mammary tumors in mice
and 2) provoke EC activities coupled to angiogenesis both in vitro
and in vivo.
Materials and Methods
Retroviral Plasmids, Transgenic Expression, and Recombinant
CystC Protein Purification
Control (i.e., green fluorescent protein [GFP]), CystC-, and
Δ14CystC-expressing NMuMG cells were described and character-
ized previously [12]. Malignant metastatic 4T1 cells were purchased
from ATCC (Manassas, VA) and were cultured as described previously
[14], whereas murine brain microvascular MB114 ECs were generously
supplied by Dr. Michael Hart (University of Wisconsin, Madison, WI)
and were cultured as described previously [15]. Human umbilical vein
ECs (HUVECs; passages 3-6) were purchased from Cambrex Cor-
poration (East Rutherford, NJ) and were cultured in endothelial cell
growth media-2 media supplemented with EC growth factors accord-
ing to the supplier’s instructions. Bicistronic retroviral vectors encoding
for human CystC or Δ14CystC were described previously [13]. CystC
and Δ14CystC retroviral supernatants were infected into 4T1 carci-
noma or MB114 ECs, which subsequently were sorted, collected, and
expanded to yield stable polyclonal populations of transgene expressing
cells (≥95% GFP-positive) as described previously [12,13].
The construction of bacterial expression vectors encoding for hu-
man CystC or Δ14CystC fused to the C-terminus of glutathione S -
transferase (GST), together with the subsequent purification of their
recombinant protein products from transformed Escherichia coli, was
performed as described [12,13].
Cell Biologic Assays
The effect of CystC or Δ14CystC expression on various TGF-β–
stimulated activities in 4T1, MB114, or HUVEC cells was deter-
mined as follows: 1) Smad2/3 and Smad1/5/8 phosphorylation was
monitored by immunoblot analysis with phosphospecific antibodies
(Cell Signaling, Beverly, MA) as described [12], 2) cell invasion was
induced by 2% serum in a modified Boyden chamber coated with
Matrigel matrices (diluted 1:50 in serum-free media) as described
[12,13], 3) synthetic gene expression was assessed in p3TP- and pSBE-
luciferase reporter gene assays as described [12,13], 4) anchorage-
independent cell growth during a 10-day period as described previously
[12], 5) angiogenic sprouting in rat tail collagen matrices as described
[16], and 6) endogenous transcript expression was measured using
semiquantitative real-time polymerase chain reaction (PCR) as de-
scribed previously [16]. The oligonucleotide primer pairs used to
analyze the expression of MT1–matrix metalloproteinase (MMP),
MT2-MMP, MT3-MMP, MMP2, MMP3, MMP9, tissue inhibitor
of metalloproteinase 1 (TIMP1), TIMP2, and thrombospondin 1 were
described previously [16]. Additional oligonucleotide primer pairs used
detecting the expression of PAI-1, ALK-1, ALK-5, Smad1, Smad2,
Smad3, Smad5, ID1, ID2, and ID3 are provided in Table W1. Addi-
tional detailed descriptions of these procedures are provided in Supple-
mentary Materials and Methods.
Tumor Growth and Metastasis Studies
Control (i.e., GFP)-, CystC-, or Δ14CystC-expressing 4T1 cells
were resuspended in sterile PBS and subsequently were injected
(12,000 cells per mouse) orthotopically into the mammary fat pads
of 6-week-old female syngeneic Balb/C mice (three mice per condi-
tion; Jackson Labs, Bar Harbor, ME). Mice were monitored daily,
and primary tumors were measured with digital calipers (Fisher Sci-
entific, Pittsburgh, PA) every other day beginning on day 10 after
inoculation. Tumor volumes were calculated using the following
equation: tumor volume = x2y0.5, where x is the tumor width and
y is the tumor length. Thirty days after inoculation, the mice were
killed, and their primary tumors were excised, weighed, and pro-
cessed for histopathologic analysis in the Pathology Core, University
of Colorado Cancer Center. At the time of necropsy, the lungs were
removed, minced, and digested proteolytically in PBS supplemented
with 1 mg of Blendzyme (Roche Applied Science, Indianapolis, IN).
Enzymatic reactions were allowed to proceed for 3 hours at 37°C
under continuous rotation and, subsequently, were filtered through
70-μm nylon cell strainers. The resulting single-cell suspensions were
washed twice in PBS before culturing the cells (1 × 106 cells per
plate) onto 10-cm plates in Dulbecco’s modified Eagle’s medium/
10% FBS media supplemented with 60 μM 6-thioguanine to select
for metastatic 4T1 cells, which are resistant to 6-thioguanine treat-
ment. After 14 days of growth in selection media, the resulting met-
astatic foci were fixed in 10% MeOH/10% acetic acid and stained
with crystal violet. Finally, serial histologic sections of control (i.e.,
GFP)-, CystC-, or Δ14CystC-expressing 4T1 tumors that were stained
with phosphospecific antibodies against Smad2 (1:50 dilution; Cell
Signaling Technology, Danvers, MA), p38 mitogen-activated protein
kinase (MAPK, 1:100 dilution; Cell Signaling Technology), and extra-
cellular signal–regulated kinase 1/2 (ERK1/2, 1:100 dilution; Cell Sig-
naling Technology), with antibodies against Ki-67 (1:300 dilution; BD
Biosciences, San Jose, CA), with antibodies against CD31 (1:400 di-
lution; Dako, Denmark), with Masson’s trichrome according to the
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manufacturer’s recommendations (Sigma, St. Louis, MO), and with
hematoxylin as previously described [17].
All animal studies were performed three times in their entirety and
were performed according to animal protocol procedures approved
by the Institutional Animal Care and Use Committee of University
of Colorado Denver.
In Vivo Angiogenesis Assay
The effect of CystC and Δ14CystC on TGF-β–stimulated angio-
genesis in vivo was investigated using the Matrigel implantation
essentially as described previously [16]. Briefly, 4- to 6-week-old
C57BL/6 female mice were injected subcutaneously in the ventral
groin area with Matrigel (500 μl per injection) supplemented with dil-
uent (PBS), or with basic fibroblast growth factor (bFGF, 300 ng/ml;
R&D,Minneapolis, MN) together with TGF-β1 (5 ng/ml), and recom-
binant (50 μg/ml) GST, GST-CystC, or GST-Δ14CystC. Ten days after
implantation, mice were killed, and their Matrigel plugs were removed,
fixed in 10% formalin, and sectioned in the Pathology Core, University
of Colorado Cancer Center. Afterward, the sections were stained using
the Masson’s trichrome procedure to visualize infiltrating vessels, which
were quantified under a light microscope by determining the average
number of vessels present in 10 independent fields per slide on three
independent slides. Three mice were used for each experimental con-
dition, and this experiment was performed three times in its entirety.
All animal studies were performed according to protocol procedures
approved by the Institutional Animal Care and Use Committee of Uni-
versity of Colorado Denver.
Results
CystC Inhibits 4T1 Tumor Growth and Pulmonary Metastasis
Stimulated by TGF-β
We previously established CystC as a novel antagonist of onco-
genic TGF-β signaling in a variety of normal and malignant cells,
including murine and human MECs [12,13]. Whether these in vitro
inhibitory activities of CystC could be translated to in vivo models
of breast cancer growth and metastasis stimulated by TGF-β re-
mains unknown. To address this important question, we infected
malignant metastatic murine 4T1 breast cancer cells with murine
ecotropic retroviruses encoding for either control (i.e., GFP), CystC,
or Δ14CystC, which lacks the cysteine protease inhibitor signature
(i.e., residues 80-93) and thus is incompetent to inactivate cathepsin
proteolytic activity but remains competent to antagonize TGF-β sig-
naling [13]. We chose to study 4T1 breast cancer cells for two major
reasons. First, the injection of human breast cancer cells into mice
requires the use of immunocompromised animals, which can severely
limit the interpretation of measured tumor behavior because of the
absence of immunosurveillance in the animal. Second, TGF-β is a
potent immunosuppressive agent that plays a critical role in main-
taining immune system tolerance to self-antigens and in initiating
and resolving inflammatory reactions. Moreover, the immunosup-
pressive activities of TGF-β can contribute to cancer progression in
part by inhibiting immunosurveillance mediated by infiltrating lym-
phocytes. Our use of 4T1 cells circumvents these limitations and is
bolstered further by recent findings from our laboratory [17,18] and
from others’ [19–21], establishing 4T1 cells as an important late-
stage model of TGF-β–responsive breast cancer. Figure W1A shows
that 4T1 cells transduced with CystC-based retroviruses readily se-
creted recombinant CystC or Δ14CystC proteins into the media,
whereas those transduced with control (i.e., GFP) retrovirus ex-
pressed only low levels of endogenous CystC expression. Similar to
what we observed previously in NMuMG and MDA-MB-231 cells
[12], we found that the expression of either CystC or Δ14CystC to
significantly inhibit TGF-β stimulation of 4T1 cell 1) invasion (Fig-
ure W1A), 2) p3TP- and pSBE-luciferase reporter gene expression
(Figure W1B), and 3) anchorage-independent growth (Figure W1C ).
Collectively, these findings confirmed that CystC can suppress the
oncogenic activities of TGF-β in malignant metastatic 4T1 cells.
We next analyzed whether CystC and Δ14CystC were able to an-
tagonize the ability of TGF-β to promote the growth and pulmonary
metastasis of 4T1 tumors produced in syngeneic Balb/C mice. Con-
sistent with these in vitro findings, the growth (Figure 1A), weight
(Figure 1B), and proliferative index (Figure 1C ) of 4T1 tumors in
Balb/C mice were inhibited significantly by their expression of either
CystC or Δ14CystC. In addition, 4T1 cells are resistant to the cyto-
toxic activities of 6-thioguanine, and as such, metastatic 4T1 cells
can be isolated by clonogenic assay of single-cell suspensions derived
from the lungs of tumor bearing mice [17]. As shown in Figure 1D,
the expression of CystC or Δ14CystC significantly reduced the pul-
monary metastasis of 4T1 tumors produced in Balb/C mice. We also
performed immunohistochemistry on primary tumor sections to
monitor the activation status of Smad2, p38 MAPK, and ERK1/2.
Figure 2 shows that the phosphorylation and activation of all three
TGF-β effectors were inhibited significantly in 4T1 tumors express-
ing either CystC or Δ14CystC compared with their control counter-
parts. Recently, elevated expression of ID1 and ID3 were associated
with a pulmonary metastatic gene signature and with the proliferation
of newly established pulmonary micrometastases [22]. We therefore
compared the changes in ID family member expression regulated
by TGF-β in normal NMuMG and malignant metastatic 4T1 cells
and, in doing so, found that TGF-β significantly suppressed the
expression of ID1, ID2, and ID3 in NMuMG cells (Figure W2, A–
C). In stark contrast, 4T1 cells readily upregulated their expression of
ID1 and ID3 when treated with TGF-β (Figure W2, A–C), consistent
with a role of these IDs in mediating pulmonary metastasis by TGF-β.
More importantly, expression of CystC or Δ14CystC significantly
reduced ID family member expression regulated by TGF-β (Fig-
ure W2D), suggesting that the ability of CystC to suppress breast
cancer metastasis stimulated by TGF-β transpires in part through
diminished ID1 and ID3 expression in metastatic MECs. Taken to-
gether, these findings demonstrate the efficacy of CystC to target
and inhibit the oncogenic activities of TGF-β in late-stage mammary
tumors produced in mice.
CystC Inhibits Angiogenesis in 4T1 Tumors Produced in Mice
Angiogenesis is essential to tumor progression through its ability
to provide developing neoplasms a supply of nutrients, a means for
waste removal, and a route for metastatic cell dissemination to sec-
ondary organ sites [6]. TGF-β plays critical roles in regulating both
the activation and the resolution phases of angiogenesis [7,23–25],
and as such, we analyzed the effect of CystC and Δ14CystC expres-
sion on the degree of angiogenesis in 4T1 tumors produced in mice.
To do so, control (i.e., GFP)-, CystC-, and Δ14CystC-expressing
4T1 tumor sections were treated with Masson’s trichrome, which
stains collagen fibers blue and erythrocytes red. Figure 3A shows that
control 4T1 tumors contained well-developed vessels that were filled
with erythrocytes, particularly along the tumor edges. This suggests
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that 4T1 tumors indeed formed functional capillaries during their de-
velopment and progression within the mammary fat pads of Balb/C
mice, which contrasts sharply with the poorly formed and sporadically
distributed vessels detected in CystC- or Δ14CystC-expressing 4T1
tumors (Figure 3A). We quantified the differences in tumor angiogen-
esis by staining these tumor slices with the EC marker, CD31, which
showed that CystC and Δ14CystC both significantly reduced the
microvessel densities in 4T1 tumors compared with their control
counterparts (Figure 3B). Taken together, these findings provide the
first demonstration that CystC possesses potent angiostatic activity
against mammary tumors. Moreover, because Δ14CystC lacks inhibi-
tory activity against cathepsins [13], but retains full antagonistic activ-
ity against TGF-β, these findings also suggest that CystC may limit
vessel development in tumors by uncoupling TGF-β from angiogene-
sis activation.
CystC Inhibits TGF-β Signaling in ECs
As an initial step in addressing the previously mentioned hypoth-
esis, we examined whether quiescent murine brain MB114 microvas-
cular cells upregulate their production of CystC when stimulated with
TGF-β. Figure W3 shows that treating MB114 cells with TGF-β stim-
ulated the production of CystC transcripts and protein, thereby estab-
lishing CystC as a novel gene target of TGF-β in ECs as well as a
potential regulator of EC response to TGF-β. We tested the latter sup-
position by infecting MB114 cells with retroviruses encoding control
(i.e., GFP), CystC, or Δ14CystC (Figure W4A) and subsequently
monitoring their responses to TGF-β. Similar to their effects on
TGF-β signaling in normal and malignant MECs (Figures W1 and
W2) [12], the expression of either CystC or Δ14CystC significantly
inhibited TGF-β stimulation of MB114 cell invasion (Figure W4A)
and luciferase reporter gene expression (Figure W4B). Similar inhib-
itory actions on TGF-β–stimulated cell invasion and reporter gene ex-
pression were observed after administration of either recombinant
CystC or Δ14CystC to MB114 cells (Figure W4, C and D).
We also determined the consequences of CystC expression in reg-
ulating endogenous transcript production in quiescent and TGF-β–
stimulated MB114 cells. In doing so, we limited our analyses to
MB114 cells that expressed Δ14CystC because this CystC derivative
is fully competent in antagonizing TGF-β signaling but has lost its
ability in inhibiting cathepsin proteolytic activity [12,13]. Thus, differ-
ences in gene expression detected by semiquantitative real-time PCR
likely reflect altered activation of the TGF-β signaling system as op-
posed to a combination of altered activation of the TGF-β and cathep-
sin signaling systems. Figure W5 shows that Δ14CystC selectively
inhibited the expression of effector molecules operant in mediating
the physiological activities of TGF-β, including that of ALK-5, Smad2,
Figure 1. CystC inhibits 4T1 tumor growth and pulmonary metastasis. (A and B) Control (Con.)-, CystC-, or Δ14CystC-expressing 4T1
cells were injected orthotopically into the mammary fat pads of Balb/C mice. Ten days after injection, tumor volumes were measured
every second day until they were killed on day 30. Data are mean (±SE) tumor volumes (A) or wet weights (B) observed in three indepen-
dent experiments. (C) Tumor sections were stained with antibodies against Ki-67. Accompanying data are the mean (±SE) proliferating
tumor cells (brown) relative to those present in sections of control 4T1 tumors. (D) Lung single-cell suspensions were cultured onto 10-cm
plates supplemented with 6-thioguanine (60 μM). After 14 days, the surviving metastatic colonies were fixed, stained with crystal violet,
and counted. Data are mean (±SE) surviving colonies per plate observed in three independent experiments. *P < .05, Student’s t test.
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and Smad3 (Figure W5A). Moreover, these same cellular conditions
reversed the ability of TGF-β to repress the expression of ID1 and
ID2 in MB114 cells (Figure W5B). Finally, we observed Δ14CystC
to significantly augment the expression of MT1-MMP induced by
TGF while simultaneously attenuating that of MT3-MMP in these
same cells (Figure W5C). Along these lines, we detected a trend to-
ward diminished coupling of TGF-β to the expression of MMPs 2, 3,
and 9 in Δ14CystC-expressing MB114 cells, findings consistent with
the anti-invasive activity possessed by Δ14CystC (Figure W5C ).
We also addressed whether the anti–TGF-β activities of CystC
were unique to MB114 cells or were instead a more generalized phe-
nomenon in ECs. As expected, administration of recombinant CystC
to MB114 cells specifically inhibited the ability of TGF-β to stimu-
late the phosphorylation of Smad2/3 but failed to alter its coupling to
the activation of Smad1/5/8 in MB114 cells (Figure 4A). Repeating
this experiment in human HUVEC cells demonstrated that CystC
antagonized the phosphorylation of Smad2/3 stimulated by TGF-β
and reduced its activation of Smad1/5/8 (Figure 4B). Thus, CystC
also inhibited TGF-β signaling in human ECs, which significantly
impaired their ability to induce luciferase reporter gene expression
(Figure 4C ) and undergo invasion when stimulated with TGF-β
(Figure 4D). Collectively, these findings demonstrate that the anti–
TGF-β activities of CystC can be extended to include a generalized
angiostatic function in ECs.
CystC Inhibits TGF–β–Stimulated Angiogenesis and Vessel
Development In Vitro and In Vivo
We demonstrated previously that overlaying quiescent MB114 cell
monolayers with FBS-supplemented rat tail collagen induces their for-
mation of angiogenic sprouts that ultimately give rise to the generation
of three-dimensional capillary-like networks [15,16]. We used this as-
say here and found TGF-β to possess significant angiogenic activity in
control MB114 cells but not in their CystC- or Δ14CystC-expressing
counterparts (Figure 5, A and B). Similar inhibitory actions on TGF-
β–stimulated angiogenic sprouting were observed after administration
of either recombinant CystC or Δ14CystC to MB114 cells (Fig-
ure 6C ). Thus, these analyses identify TGF-β as a proangiogenic factor
for MB114 cells, whose ability to initiate tubulogenesis in response to
TGF-β is neutralized by CystC and its analog, Δ14CystC. These find-
ings also suggest that CystC administration may serve to alleviate the
angiogenic activities of TGF-β in vivo. We tested this hypothesis by
using the Matrigel plug implantation assay, which monitors the ability
of various angiogenic agents to alter the neovascularization of Matrigel
plugs implanted subcutaneously into mice. Figure 6 shows that bFGF
stimulated significant neovascularization of implanted Matrigel plugs
and that this angiogenic response was further enhanced by TGF-β.
Whereas inclusion of recombinant GST into the Matrigel mixtures
failed to alter vessel development in mice, addition of either recombi-
nant CystC or Δ14CystC significantly impaired the development and
infiltration of vessels into implanted Matrigel plugs stimulated by the
combination of bFGF and TGF-β (Figure 6). Collectively, these find-
ings demonstrate that the ability of TGF-β to stimulate angiogenesis in
genetically normal mice can be targeted chemotherapeutically by ad-
ministration of CystC.
Discussion
The uncoupling of TGF-β from cytostasis often serves as a prelude
for its ability to stimulate the eventual growth, invasion, and metas-
tasis of developing and progressing mammary tumors. The oncogenic
character of TGF-β in late-stage cancers has generated considerable
effort to discover novel chemotherapeutics capable of inactivating
the tumor promoting activities of TGF-β in patients with late-stage,
metastatic disease, particularly in breast cancer patients. Included in
this growing list of potential TGF-β chemotherapeutics are 1) large-
molecule TGF-β antagonists, such as monoclonal TGF-β antibodies,
Figure 2. CystC inhibits oncogenic TGF-β signaling in 4T1 tumors
produced in mice. Tumor sections were stained with phosphospe-
cific antibodies against Smad2 (A), p38 MAPK (B), or ERK1/2 (C).
The extent of immunoreactivity was quantified by measuring sig-
nal pixel densities using NIH Image J. Accompanying data are the
mean (±SE) immunoreactive tumor cells relative to those ob-
served in control (Con.) tumors in three independent experiments.
*P < .05, Student’s t test.
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Figure 4. CystC inhibits TGF-β signaling in murine and human ECs. Quiescent MB114 (A) or HUVEC (B) cells were pretreated with re-
combinant (10 μg/ml) GST or CystC as indicated before their stimulation with TGF-β1 (2.5 ng/ml) for 30 minutes at 37°C. Afterward, the
phosphorylation status of Smad2/3 and Smad1/5/8 was monitored by immunoblotting with phosphospecific antibodies against these
transcription factors as indicated. Differences in protein loading were monitored by reprobing stripped membranes with β-actin anti-
bodies. Data are from a representative experiment that was repeated twice with similar results. (C) HUVEC cells were transiently trans-
fected with p3TP-luciferase cDNA and pCMV-β-gal cDNA and, subsequently, were stimulated with increasing concentrations of TGF-β1
(0-5 ng/ml) in the absence or presence of recombinant (10 μg/ml) GST, GST-CystC, or GST-Δ14CystC as indicated. Data are the mean
(±SE) fold inductions of luciferase activity relative to unstimulated GST-treated MB114 cells observed in four independent experiments.
(D) Control or TGF-β1–stimulated (5 ng/ml) HUVEC cells were allowed to invade through synthetic basement membranes for 48 hours in
the presence or absence recombinant (10 μg/ml) GST or GST-CystC as indicated. Data are mean (±SE) invasion relative to that induced
by 2% FBS in the presence of GST observed in three independent experiments. *P < .05, Student’s t test.
Figure 3. CystC inhibits angiogenesis in 4T1 tumors produced in mice. (A) Tumor sections were subjected to Masson’s trichrome to
visualize red blood cells (red stain) and collagen fibers (blue stain). CystC- or Δ14CystC-expressing 4T1 tumors exhibit malformed and
unevenly distributed vessels compared with their control counterparts. (B) Tumor sections also were stained with antibodies against
CD31. Accompanying data are the mean (±SE) vessels per field in control (Con.)-, CystC-, or Δ14CystC-expressing 4T1 tumors observed
in three independent experiments. *P < .005, Student’s t test.
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soluble TβR-II:Fc fusion proteins, and antisense oligonucleotides, and
2) small-molecule TGF-β antagonists that target the ATP-binding sites
of TβR-I and TβR-II [1,26,27]. In general, the use of these TGF-β–
targeted therapies in preclinical animal models has yielded mixed re-
sults within specific tumor microenvironments, wherein they either
alleviate or exacerbate disease development in a manner predicted by
the TGF-β paradox [28]. Thus, there remains a significant scientific
and clinical need for the development of safe and effective anti–
TGF-β chemotherapies that minimize off-target adverse reactions.
We identified CystC as a TGF-β gene target in fibroblasts and as a
molecule whose expression is downregulated significantly in 44% of
human cancers [13]. More importantly, we established CystC and its
engineered derivative, Δ14CystC, as novel TβR-II antagonists that
inhibit oncogenic TGF-β signaling in normal and malignant MECs
[12,13]. Despite these interesting findings, the question remained as
to whether the in vitro anti–TGF-β activities could be recapitulated
in and translated to in vivo models of breast cancer regulated by
TGF-β and as to whether elevated CystC concentrations within these
same mammary tumor microenvironments might also target TGF-β
signaling in various stromal components, particularly ECs and their
initiation of tumor angiogenesis. We show for the first time that de-
livering CystC to late-stage aggressive mammary tumors indeed di-
minish their capacity to grow and metastasize in genetically normal
mice (Figure 1). Besides its ability to antagonize TGF-β signaling di-
rectly in breast carcinoma cells (Figure 2), CystC also was shown for
the first time to 1) limit mammary tumorigenesis by inhibiting an-
giogenesis (Figure 3) and 2) uncouple TGF-β from stimulating an-
giogenic activities in ECs both in vitro (Figures 4 and 5) and in vivo
(Figure 6). It should be noted that the role of cysteine proteases in
promoting tumorigenesis has been recognized for decades [29] and
that inhibiting cysteine protease activity can prevent tumor angio-
genesis, invasion, and extracellular matrix degradation [30–33]. In-
terestingly, we find CystC and Δ14CystC, which lack anti–cysteine
protease activity [13], to be equipotent in suppressing mammary tu-
mor growth, metastasis, and angiogenesis in mice, which suggests
that the primary antitumor activity of CystC transpires in part by
antagonizing the ability of TGF-β to bind TβR-II [13]. However, al-
though our findings clearly support an anti–TGF-β activity as the
major mode of action whereby CystC suppresses mammary tumor
growth and progression in mice, they do not rule out or exclude al-
ternative mechanisms that facilitate the ability of CystC to inhibit
tumorigenesis. Indeed, we recently observed CystC administration
to impact the response of carcinoma and ECs to bone morphogenic
proteins 6 and 7 (M. Tian and W. P. Schiemann, unpublished ob-
servations). Thus, given the ability of the distant CystC relative, fetuin,
to inhibit TGF-β and bone morphogenic protein signaling [34,35], it
remains plausible that CystC functions as a general regulator of the
activities and functions of TGF-β superfamily members. Similarly, it
also remains possible that CystC inhibits tumorigenesis through ad-
ditional protease-independent mechanisms reminiscent of those attrib-
uted to TIMP-3, which antagonizes angiogenesis by preventing vascular
endothelial growth factor (VEGF) binding to VEGFR2 [36]. Indeed,
our broad-spectrum delivery of CystC and Δ14CystC to mammary
tumor microenvironments likely mediates additional TGF-β–specific
and –nonspecific activities in tumor-associated stroma and infiltrating
immune cells, whose altered function and behavior in response toCystC
administration clearly warrants examination. Finally, we recently ob-
served that administration of small-molecule TβR-I antagonists in-
duce a partial epithelial-mesenchymal transition in normal MECs that
Figure 5. CystC inhibits TGF-β–stimulated angiogenic sprouting in
MB114 cells. (A) Control (Con.)-, CystC-, or Δ14CystC-expressing
MB114 cells were cultured on rat tail collagen gels for 10 days in
the presence or absence of 10% FBS or 10% FBS/TGF-β1 (5 ng/ml)
as indicated. Representative images of sprouting cultures are shown
(original magnification, ×200). (B) The quantity of invading angiogenic
sprouts was determined by counting 10 independent fields per well
under a light microscope. Data are the mean (±SE) quantity of an-
giogenic sprouts normalized to unstimulated control MB114 cells
observed in three independent experiments. (C) Control or TGF-β1–
stimulated (5 ng/ml) MB114 cells were cultured on rat tail collagen
gels for 10 days in the presence of recombinant (10 μg/ml) GST,
GST-CystC, or GST-Δ14CystC proteins as indicated. The quantity of
invading angiogenic sprouts was determined by counting 10 inde-
pendent fields per well under a light microscope. Data are the mean
(±SE) quantity of angiogenic sprouts normalized to unstimulated
MB114 cells observed in three independent experiments.
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diminishes their epithelial character and morphology (T. M. Allington
and W. P. Schiemann, unpublished observations). Importantly, these
untoward morphologic and phenotypic adverse effects are not detected
in normal MECs treated with either CystC or Δ14CystC [12], suggest-
ing that elevated CystC concentrations seem to be well tolerated by nor-
mal MECs and mammary tissues, which further supports the potential
development and application of CystC in clinical settings for patients
with advanced breast cancer.
TGF-β expression is frequently upregulated in developing and
progressing tumors, and this event has been associated with increas-
ing tumor severity and grade [1,2]. Elevated TGF-β expression also
plays a prominent role in directing autocrine and paracrine signaling
networks within tumor microenvironments, which ultimately pro-
motes tumor growth, invasion, and metastasis [1,37]. In addition,
TGF-β also can instruct carcinoma cells to remodel their extracellular
matrix in a manner that favors tumor invasion and metastasis [38,39].
Along these lines, elevated expression of ID1 has been associated with
the ability of breast cancer cells to invade and metastasize to the lung
[22], whereas ID1 and ID3 are necessary for EC progenitors to con-
tribute to tumor angiogenesis [40,41]. Interestingly, TGF-β has been
reported to be an important regulator of ID family member expression
[42–44]. For instance, TGF-β was observed to chronically repress the
expression of ID2 and ID3 in normal and malignant epithelial cells
[45] but was found to induce the expression of ID1 and ID3 in fibro-
blasts [46]. Thus, TGF-β regulates ID family member expression in a
cell- and context-specific manner. Consistent with this notion, we ob-
served TGF-β to significantly repress the expression of ID1, ID2, and
ID3 in normal MECs, a finding that contrasted sharply with the sig-
nificant induction of ID1 and ID3 expression in malignant metastatic
4T1 cells stimulated with TGF-β (Figure W2). Importantly, the
expression of either CystC or Δ14CystC in 4T1 cells significantly in-
hibited their expression of ID1 to ID3 in response to TGF-β (Fig-
ure W2), thereby identifying a potentially important mechanism to
uncouple TGF-β from ID family member expression and, consequently,
to limit the malignancy of late-stage breast cancers. Future studies clearly
need to explore more thoroughly this idea and the potential for CystC
Figure 6. CystC inhibits TGF-β–stimulated angiogenesis and vessel development in genetically normal mice. C57BL/6 female mice were
injected subcutaneously with Matrigel supplemented with diluent (i.e., PBS), bFGF (300 ng/ml), or bFGF (300 ng/ml) in combination with
TGF-β1 (5 ng/ml) in the presence of recombinant (20 μg/ml) of GST, GST-CystC, or GST-Δ14CystC as indicated. Mice were killed on day 10,
and the resulting plugs were harvested, fixed, sectioned, and stained with Masson’s trichrome to visualize infiltrating blood vessels [de-
noted by arrow heads (A)], which were subsequently quantified by counting 10 independent fields per slide under a light microscope (B).
Data are the mean (±SE) vessel densities relative to bFGF treatment observed in three independent experiments. *P< .05, Student’s t test.
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to uncouple TGF-β from the regulation of epithelial-mesenchymal
transition–generated “stemness” in malignant metastatic MECs.
In addition to its ability to stimulate carcinoma invasion and me-
tastasis, TGF-β has also been linked to both the activation and res-
olution phases of angiogenesis, presumably through its differential
activation of ALK-1 versus ALK-5 in ECs [7,8,23]. For instance, ac-
tivation of ALK-5 by TGF-β stimulates Smad2/3 and the production
of PAI-1 and fibronectin, which collectively promote angiostasis and
vessel maturation [42,47–49]. In contrast, activation of ALK-1 by
TGF-β stimulates Smad1/5/8 and the expression of angiogenic
genes, such as Id1 and interleukin 1 receptor–like 1 [42,47–49], which
collectively promote angiogenesis activation. Moreover, ALK-1 sig-
naling stimulated by TGF-β requires this cytokine to initially acti-
vate TβR-II and ALK-5, which then recruit and activate ALK-1
after its association with TβR-II:ALK-5:TGF-β ternary complexes
[47]. Thus, activation of ALK-1 and the induction of angiogenesis
by TGF-β must first proceed through its assembly of angiostatic
TGF-β receptor complexes (i.e., TβR-II:ALK-5). At present, the mo-
lecular mechanisms that initially exclude and then recruit ALK-1 to
angiostatic TGF-β receptor complexes remain unknown but may re-
flect a delicate balance between TGF-β and other angiogenic factors
located within tumor microenvironments. Indeed, low TGF-β con-
centrations enhance the ability of bFGF and VEGF to stimulate EC
proliferation and angiogenic sprouting, whereas high TGF-β concen-
trations inhibit these angiogenic activities [25,50]. Along these lines,
the proangiogenic functions of TGF-β also have been linked to its
ability to regulate the expression and/or activities of other angiogenic
factors, such as bFGF and VEGF [9]. It is interesting to note that
inclusion of TGF-β to Matrigel plugs implanted into mice only pro-
moted angiogenesis and vessel development in the presence of bFGF
and its ability to create a proangiogenic microenvironment (data not
shown). Thus, it is plausible that the recruitment of ALK-1 to angio-
static TGF-β receptor complexes may first require the stimulation of
accessory angiogenic signals or proteins within activated EC micro-
environments. The existence of such a scenario seems unlikely for
several reasons. First, CystC administration had no appreciable effect
on the coupling of TGF-β to the activation of Smad1/5/8 in MB114
cells (Figure 4), despite the overall effectiveness of CystC to antago-
nize angiogenesis stimulated by TGF-β. Moreover, we observed CystC
administration to selectively downregulate the expression signaling
molecules targeted by ALK-5, not those targeted by ALK-1 (Fig-
ure W5), which is consistent with the presence of distinct ALK-5
and ALK-1 signaling systems in ECs. Second, our findings suggest that
the activation of ALK-1 by TGF-β is dissociated from its stimulation
of TβR-II:ALK-5 signaling complexes. This notion is supported by
several recent studies showing that 1) ALK-1 and ALK-5 are expressed
in a discordant and nonoverlapping manner in blood vessels [51] and
2) ALK-5 and TβR-II activity are not required for ALK-1 function in
ECs [52]. Finally, crystal structure analyses of TGF-β3 bound to the
extracellular domains of TβR-I and TβR-II indicate that the molecu-
lar interactions necessary for ALK-1 binding are distinct from those
operant in mediating the binding of ALK-5, making it unlikely that
ALK-1 binds directly to or is readily recruited into active TβR-II:ALK-5
complexes [53]. In addition, there remains considerable debate as to
whether ALK-1 signaling does in fact mediate angiogenesis activation
and, conversely, whether ALK-5 signaling does in fact mediate angio-
genesis resolution [42,47,51,54,55]. Our findings in MB114 cells are
consistent with the notion that ALK-5 couples directly to angiogenesis
activation, an event that is readily antagonized by CystC administration.
Future studies analyzing the angiogenic activities of TGF-β in ALK-1–
and ALK-5–deficient MB114 cells clearly are warranted to address this
issue, as are studies aimed at determining whether the activation of
ALK-1 by TGF-β requires additional accessory receptor molecules or
angiogenic factors.
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Supplementary Materials and Methods
Immunoblot Analyses
The expression and secretion of recombinant CystC and Δ14CystC
proteins by infected 4T1 and MB114 cells was monitored by immu-
noblotting conditioned medium with anti-CystC antibodies as de-
scribed [1,2]. The effect of recombinant GST, CystC, or Δ14CystC
on the ability of TGF-β to stimulate the phosphorylation of Smad2
or Smad1/5/8 phosphorylation was determined by allowing MB114
or HUVEC cells (100,000 cells per well) to adhere overnight to
24-well plates. The following morning, the cells were washed twice
in ice-cold PBS and incubated in serum-free medium supplemented
with 10 μg/ml of recombinant GST, CystC, or Δ14CystC for
2 hours at 37°C. Afterward, the cells were stimulated with TGF-β1
(2.5 ng/ml) for 30 minutes at 37°C and, subsequently, were subjected
to phospho-Smad2 (1:500 dilution;Cell SignalingTechnology,Danvers,
MA) or phospho-Smad1/5/8 (1:500 dilution; Cell Signaling Tech-
nology). Differences in protein loading were monitored by reprobing
stripped membranes with antibodies against β-actin (1:1000; Santa
Cruz Biotechnology, Santa Cruz, CA).
Invasion Assays
The effect CystC and Δ14CystC on the invasion of 4T1 or MB114
cells was determined as described previously [1,2]. Briefly, upper cham-
bers were coated with 100 μl of diluted Matrigel (1:50 in serum-
free media; BD Biosciences, San Jose, CA), which was evaporated to
dryness overnight at room temperature. The following morning, the
Matrigel mixtures were rehydrated and, subsequently, were cultured
with control (i.e., GFP)-, CystC-, or Δ14CystC-expressing 4T1 or
MB114 cells at a density of 100,000 cells per chamber. Cellular inva-
sion was stimulated by the addition of 2% serum to the lower cham-
bers and by the addition of TGF-β1 (5 ng/ml) to the upper chambers
as indicated. Forty-eight hours later, the cells were washed in ice-cold
PBS and immediately fixed for 15 minutes with 95% ethanol. Cells
remaining in the upper chambers were removed with a cotton swab,
whereas those remaining in the lower chamber were stained with
crystal violet. The extent of cellular invasion was quantified using
the NIH Image J software package to measure the optical density of
the stained cells.
In some experiments, the effect of recombinant GST, CystC, and
GST-Δ14CystC on MB114 and HUVEC cell invasion was exam-
ined. To do so, MB114 or HUVEC cells (100,000 cells per cham-
ber) were allowed to invade through Matrigel in the absence or
presence of 10 μg/ml of recombinant GST, GST-CystC, or GST-
Δ14CystC, together with or without TGF-β1 (5 ng/ml) as indicated.
All subsequent procedures were performed as described previously.
Luciferase Reporter Gene Assays
Analysis of luciferase activity driven by the synthetic p3TP or pSBE
was performed as described previously [1,2]. Briefly, control (i.e.,
GFP)-, CystC-, or Δ14CystC-expressing 4T1 or MB114 cells were
plated in 24-well plates at density of 30,000 cells per well and allowed
to adhere overnight. The cells were transiently transfected the follow-
ing day by overnight exposure to LT1 liposomes (Mirus, Madison,
WI) that contained 300 ng/ml luciferase reporter complementary
DNA (cDNA) and 100 ng/ml pCMV-β-gal cDNA, which was used
as an internal control for transfection efficiency. Afterward, the cells
were washed twice with PBS and stimulated overnight in serum-free
medium supplemented with varying concentrations of TGF-β1. On
completion of agonist stimulations, luciferase and β-gal activities
contained in detergent-solubilized cell extracts were determined.
In some experiments, the effect of recombinant GST, GST-CystC,
or GST-Δ14CystC in altering luciferase expression in MB114 or
HUVEC cells was determined. To do so, MB114 or HUVEC cells
were transiently transfected as previously mentioned and, subse-
quently, were stimulated with varying concentrations of TGF-β1
in the absence or presence of recombinant (10 μg/ml) GST, GST-
CystC, or GST-Δ14CystC. All subsequent procedures were per-
formed as described previously.
Soft Agar Assays
The growth of 4T1 cells in soft agar was performed according to the pro-
cedures described in [1]. Briefly, triplicate cultures of control (i.e., GFP)-,
CystC-, or Δ14CystC-expressing 4T1 cells (10,000 cells per plate)
were grown in 0.3% agar on a cushion of 0.6% agar in 35-mm plates.
4T1 cell growth in the absence or presence of TGF-β1 (5 ng/ml) was
allowed to proceed for 10 days, wherein the number of colonies formed
was quantified under a light microscope in 10 independent fields.
Angiogenic Sprouting Assays
The ability of MB114 cells to form angiogenic sprouts in collagen
matrices was performed as described previously [3]. Briefly, control
(i.e., GFP)-, CystC-, or Δ14CystC-expressing MB114 cells were cul-
tured onto six-well plates at a density of 300,000 cells/well and,
subsequently, were overlaid with 2 ml per well of solidified rat tail
collagen, which was supplemented with 10% FBS to initiate angio-
genic sprouting by quiescent MB114 cells that also were treated with
or without TGF-β1 (5 ng/ml). In some experiments, recombinant
(10 μg/ml) GST, GST-CystC, or GST-Δ14CystC proteins were
mixed with rat tail collagen to assess their effects on TGF-β stimu-
lation of angiogenic sprouting by quiescent MB114 cells. Angiogenic
sprouting reactions were allowed to proceed for 7 days, at which
point the number of invading sprouts was quantified under a light
microscope by determining the average number of sprouts present in
10 independent fields per well.
Semiquantitative Real-time PCR
The effect of CystC and Δ14CystC on the ability of TGF-β to reg-
ulate gene expression in either NMuMG, 4T1, or MB114 cells was
assessed by semiquantitative real-time PCR as described previously
[3]. Briefly, control (i.e., GFP)-, CystC-, or Δ14CystC-expressing
cells were cultured onto six-well plates at a density of 300,000 cells
per well and allowed to adhere overnight. The following morning,
the cells were washed in PBS and cultured in serum-free medium
supplemented with or without TGF-β1 (5 ng/ml) for varying times
at 37°C. Afterward, total RNA was isolated using the RNeasy Plus
Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s rec-
ommendations. cDNA were synthesized by iScript reverse transcrip-
tion (Bio-Rad, Hercules, CA), which were then diluted 10-fold in
H2O and used in semiquantitative real-time PCR reactions (25 μl)
that used the SYBR Green system (Bio-Rad) supplemented with 5 μl
of diluted cDNA and 0.1 μM of oligonucleotide pairs listed below.
Polymerase chain reactions were performed and analyzed on a Bio-
Rad Mini-Opticon detection system, and differences in RNA con-
centrations were controlled by normalizing individual gene signals
to their corresponding β-actin or GAPDH RNA signals. The oligo-
nucleotide primer pairs used to analyze the expression of MT1-MMP,
MT2-MMP, MT3-MMP, MMP2, MMP3, MMP9, TIMP1, TIMP2,
and thrombospondin 1 were described previously [3]. Additional oligo-
nucleotide primer pair sequences are provided in Table W1.
Statistical Analysis
Statistical values were defined using an unpaired Student’s t test,
where P < .05 was considered significant. P values for all experiments
analyzed are indicated.
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Table W1. Primer Sets for Real-time PCR.
Gene Target Primer Orientation Sequence (5′ to 3′)
PAI-1 Forward 5′-GGTGAAACAGGTGGACTTCTCA
PAI-1 Reverse 5′-GCATTCACCAGCACCAGGCGTG
ALK-1 Forward 5′-GAGCCGTGTTCATGGTAGT
ALK-1 Reverse 5′-GGAGGAGCCAGAAGTTGAT
ALK-5 Forward 5′-ATGGGCAATAGCTGGTTTT
ALK-5 Reverse 5′-GCCATAACCGCACTGTC
Smad1 Forward 5′-GTGGAAACAGGGCGATGAAG
Smad1 Reverse 5′-GCGTCCACAGCTTTCTCTGC
Smad2 Forward 5′-GCCGTCTTCAGGTTTCACA
Smad2 Reverse 5′-TAGTATGCGATTGAACACC
Smad3 Forward 5′-CGCCAGTTCTACCTCCAGTG
Smad3 Reverse 5′-AAAGACCTCCCCTCCGATGT
Smad5 Forward 5′-CCAGCCGTGAAGCGATTG
Smad5 Reverse 5′-GCCTTTTCTGCCCATTTCTCT
ID1 Forward 5′-CCCTGAACGGCGAGATCA
ID1 Reverse 5′-TTTTTTCCTCTTGCCTCCTGAA
ID2 Forward 5′-′GAAAGCCTTCAGTCCGGTGA
ID2 Reverse 5′-TGGTCCGACAGGCTGTTTTT
ID3 Forward 5′-CTGAGGGCATGGATGAGCTT
ID3 Reverse 5′-AGGGTAAGTGAAGAGGGCTGG
Figure W1. CystC inhibits oncogenic TGF-β signaling in malignant metastatic 4T1 cells. (A) Conditioned medium from control (Con.)-,
CystC-, or Δ14CystC-expressing 4T1 cells was tumbled with Ni2+-agarose to capture recombinant CystC proteins, which were visualized
by immunoblotting anti-CystC antibodies. These same 4T1 derivatives were allowed to invade through synthetic basement membranes
in the presence or absence of TGF-β1 (5 ng/ml) for 48 hours. Data are mean (± SE) invasion relative to that induced by 2% FBS in control
4T1 cells observed in three independent experiments. (B) Control (Con.)-, CystC-, or Δ14CystC-expressing 4T1 cells were transiently
transfected with pCMV-β-gal, together with either p3TP- or pSBE-luciferase plasmids as indicated, and subsequently were stimulated
overnight with TGF-β1 (5 ng/ml) as indicated. Afterward, the luciferase and β-gal activities contained in detergent-solubilized cell extracts
were determined. Data are mean (±SE) fold inductions of luciferase activity relative to unstimulated control cells observed in four inde-
pendent experiments. (C) Control (Con.)-, CystC (CC)-, or Δ14CystC (Δ14)-expressing 4T1 cells were cultured in soft agar in the absence or
presence of TGF-β1 (5 ng/ml) for 10 days, wherein 4T1 colony formation was quantified by light microscopy. Data are the mean (±SE)
colony formation relative to TGF-β1–treated control 4T1 cells observed in three independent experiments. *P < .05, Student’s t test.
Figure W2. CystC antagonizes ID1-3 expression regulated by TGF-β in 4T1 cells. (A–C) Quiescent NMuMG and 4T1 cells were incubated
in the absence or presence of TGF-β1 (5 ng/ml) for 24 hours. Afterward, total RNA was isolated and subjected to semiquantitative real-
time PCR to monitor the expression of ID1 (A), ID2 (B), or ID3 (C) as indicated. Data are the mean (±SE) changes of ID gene expression
relative to that in unstimulated NMuMG cells observed in three independent experiments. (D) Control (Con.)-, CystC-, or Δ14CystC-
expressing 4T1 cells were treated (Rx) with TGF-β1 and subjected to semiquantitative real-time PCR to monitor changes in the expres-
sion of ID1 to ID3 as previously mentioned. Data are the mean (±SE) changes of ID expression relative to that in TGF-β–stimulated
control cells observed in three independent experiments. *P < .05, Student’s t test.
Figure W3. TGF-β stimulates CystC expression in MB114 cells. (A)
Total RNA isolated from control and TGF-β–stimulated MB114
cells was reverse-transcribed before analyzing the expression of
CystC by semiquantitative real-time PCR. Data are the mean (± SE)
increase in CystC mRNA expression observed in three independent
experiments. (B) Quiescent MB114 cells were stimulated with TGF-
β1 (5 ng/ml) for 0 to 12 hours as indicated. Afterward, conditioned
mediumwas collected, concentrated, and ultimately immunoblotted
with antibodies against CystC. Differences in cell density were mon-
itored by collecting adherent MB114 cells and immunoblotting with
antibodies against β-actin. Shown are representative images from a
single experiment that was repeated twice with similar results. Ac-
companying graph depicts themean (±SE) increase in CystC expres-
sionstimulatedbyTGF-βobserved in three independentexperiments.
Figure W4. CystC inhibits TGF-β–stimulated invasion and reporter gene expression in MB114 cells. (A) Conditioned medium from Con-
trol (Con.)-, CystC-, or Δ14CystC-expressing MB114 cells was tumbled with Ni2+-agarose to capture recombinant CystC proteins, which
were visualized by immunoblotting anti-CystC antibodies. These same MB114 derivatives were allowed to invade through synthetic
basement membranes in the presence or absence of TGF-β1 (5 ng/ml) for 48 hours. Data are mean (±SE) invasion relative to that
induced by 2% FBS in control MB114 cells observed in four independent experiments. (B and D) Control (Con.)-, CystC-, or Δ14CystC-
expressing MB114 cells were transiently transfected with pCMV-β-gal, together with either p3TP- or pSBE-luciferase plasmids as indicated,
and subsequently were stimulated overnight with TGF-β1 (5 ng/ml) in the absence or presence of recombinant (10 μg/ml) GST, GST-CystC,
or GST-Δ14CystC as indicated. Afterward, the luciferase and β-gal activities contained in detergent-solubilized cell extracts were deter-
mined. Data are mean (±SE) fold inductions of luciferase activity relative to unstimulated control (B) or GST-treated (D) MB114 cells ob-
served in at least three independent experiments. (C) Control or TGF-β1-stimulated (5 ng/ml) MB114 cells were allowed to invade through
synthetic basement membranes for 48 hours in the absence or presence of recombinant (10 μg/ml) GST, GST-CystC, or GST-Δ14CystC.
Data are mean (±SE) invasion relative to that induced by 2% FBS in the presence of GST observed in three independent experiments. *P<
.05, Student’s t test.
Figure W5. CystC inhibits TGF-β–stimulated gene transcription and Smad2/3 activation in MB114 cells. (A) Control (Con.)- or Δ14CystC-
expressing MB114 cells were stimulated with or without TGF-β for 24 hours. Total RNA was isolated and subjected to semiquantitative
PCR to monitor the expression of ALK-1, ALK-5, PAI-1, and Smads 1, 2, 3, and 5 as indicated. Data are the mean (±SE; n = 4) fold
changes of target gene expression in TGF-β–stimulated Δ14CystC-expressing MB114 cells relative to their control counterparts. (B and
C) Control (Con.)- or Δ14CystC-expressing MB114 cells were stimulated with or without TGF-β for 24 hours. Total RNA was isolated and
subjected to semiquantitative PCR to monitor the expression of ID1 to ID3 (B), and of MT1-3 MMPs, TIMPs 1 and 2, TSP-1, and MMPs 2,
3, and 9 (C) as indicated. Data are the mean (±SE; n = 4) percent changes of target gene expression in TGF-β–stimulated Δ14CystC-
expressing MB114 cells relative to their untreated control counterparts. *P < .05, Student’s t test.
